CA
NZ
UK
AU
IND
US
● No company-specific announcement was found to explain the gain.
● No announcement from the company explained the gain.
● No confirmed company-specific catalyst was found.
● No company news was found to explain the jump.
● No company-specific news was found to explain the jump.
● Adjusted earnings of 18 cents a share beat a forecast loss.
● The price target was set at $6 a share.
● Its net loss narrowed to $8.4 million from $14.0 million.
Key Highlights● Bicara shares fell steeply on heavy trading volume.● The stock hit a new 52-week low.● No company news or filing explained the drop.● The company had $497.3 million in cash as of mid-2026.Bicara Therapeutics (NASDAQ:BCAX) plunged in one of the steepest declines …
● The raise also included $150 million of convertible notes.
Please wait processing your request...